ABUS (Arbutus Biopharma) Insider Ownership: 3.64 % (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABUS Arbutus Biopharma Corp ABUS
51 GF Score
Price $4.42
GF Value $50.40
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Arbutus Biopharma Insider Ownership?

Arbutus Biopharma ABUS +1.38% 51 Insider Ownership is 3.64 % as of Aug. 05, 2026. GuruFocus rates ABUS with a GF Score™ of 51/100 and a GF Value™ of $50.40 (Possible Value Trap). The stock has 3 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Arbutus Biopharma's insider ownership is 3.64%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Arbutus Biopharma's Institutional Ownership is 70.51%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Arbutus Biopharma's Float Percentage Of Total Shares Outstanding is 67.22%.

Arbutus Biopharma Insider Ownership Historical Data

* Premium members only.

The historical data trend for Arbutus Biopharma's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arbutus Biopharma Insider Ownership Chart

Arbutus Biopharma Historical Data

The historical data trend for Arbutus Biopharma can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 3.92 3.92 3.92 3.92 3.92 3.92 3.98 3.64 3.64 3.64
ABUS
51GF Score
Arbutus Biopharma Corp ABUS
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arbutus Biopharma Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 3.64 % mean?
Arbutus Biopharma (ABUS) has a Insider Ownership of 3.64 % as of Aug. 05, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Arbutus Biopharma and its competitors.
Is Arbutus Biopharma's Insider Ownership too high?
Arbutus Biopharma's current Insider Ownership is 3.64 %. Overall, Arbutus Biopharma has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Insider Ownership compare to TBPH and ANNX?
Arbutus Biopharma's Insider Ownership of 3.64 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Arbutus Biopharma and its competitors. Arbutus Biopharma's current Insider Ownership is 3.64 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $50.40, compared to a current price of $4.42 — trading 91.2% below its estimated fair value. The current Insider Ownership is 3.64 %. Arbutus Biopharma's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current Insider Ownership is 3.64 % as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arbutus Biopharma (ABUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued. The current stock price of $4.42 is trading 91.2% below its estimated GF Value™ of $50.40. GuruFocus considers Arbutus Biopharma to be Possible Value Trap.

Key valuation signals for ABUS:

  • Insider Ownership: 3.64 %
  • GF Value™: $50.40 vs. price of $4.42 (91.2% below fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arbutus Biopharma Business Description

Other Exchanges I9DN:Germany
Address 701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
51GF Score

Get the complete analysis for ABUS

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.42
Price
$50.40
GF Value